We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: MRD
MedXY News
EnglishTag

MRD

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

ELN‑DAVID technical recommendations: NGS-based FLT3‑ITD MRD testing in AML — what clinicians and labs need to know
Hematology-OncologyFLT3-ITDNGS

ELN‑DAVID technical recommendations: NGS-based FLT3‑ITD MRD testing in AML — what clinicians and labs need to know

By MedXY|Aug 15, 2026

The ELN‑DAVID 2026 technical note establishes standards for NGS-based detection of FLT3‑ITD measurable residual disease (MRD) in AML, with lab validation, reporting, timing, and clinical-use recommendations to make FLT3‑ITD MRD testing acti

Blinatumomab Consolidation in High-Risk Ph-Negative B-Cell Acute Lymphoblastic Leukemia: Insights from the GRAALL-2014/B-QUEST Study
Hematology-OncologyAlloHSCT
blinatumomab

Blinatumomab Consolidation in High-Risk Ph-Negative B-Cell Acute Lymphoblastic Leukemia: Insights from the GRAALL-2014/B-QUEST Study

By MedXY|Jul 20, 2026

The GRAALL-2014/B-QUEST study demonstrates that integrating blinatumomab into consolidation and maintenance therapy significantly improves outcomes for adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukem

CBFB::MYH11 MRD After the Second Chemotherapy Cycle: A Guide to Allogeneic Transplantation in Favorable-Risk AML
Hematology-OncologyAllogeneic Hematopoietic Cell TransplantationAML

CBFB::MYH11 MRD After the Second Chemotherapy Cycle: A Guide to Allogeneic Transplantation in Favorable-Risk AML

By MedXY|May 18, 2026

Post-cycle 2 CBFB::MYH11 MRD best predicted outcomes in favorable-risk AML. Patients with levels ≥1% had higher relapse risk, and those receiving allo-HCT in CR1 had better 3-year disease-free survival than chemotherapy consolidation.

Adding Ianalumab to Ibrutinib Induces Deep Remissions and Enables Therapy Discontinuation in Chronic Lymphocytic Leukemia
news慢性淋巴细胞白血病，免疫球蛋白水平，单克隆 B 细胞淋巴细胞增多症，癌症易感性Ianalumab

Adding Ianalumab to Ibrutinib Induces Deep Remissions and Enables Therapy Discontinuation in Chronic Lymphocytic Leukemia

By MedXY|Jan 13, 2026

A Phase Ib study reveals that adding the anti-BAFF-R antibody ianalumab to ibrutinib therapy achieves high rates of undetectable measurable residual disease (uMRD), allowing over 40% of CLL patients to successfully discontinue long-term tre

CPX‑351 in Down Syndrome–Associated Myeloid Leukemia: a dose‑sensitivity mismatch that reduced event‑free survival in the ML‑DS 2018 trial
Hematology-OncologyCPX-351Down syndrome

CPX‑351 in Down Syndrome–Associated Myeloid Leukemia: a dose‑sensitivity mismatch that reduced event‑free survival in the ML‑DS 2018 trial

By MedXY|Nov 17, 2025

In the ML‑DS 2018 trial, substituting reduced‑intensity induction with CPX‑351 led to lower 24‑month event‑free survival (69% vs 90%) despite excellent overall survival and minimal treatment‑related mortality; MRD by GATA1 NGS, trisomy 8 an

Age‑Adapted Chemotherapy Plus MRD‑Directed Transplantation Improves Safety Without Sacrificing Efficacy in Ph‑Negative Adult ALL: Key Findings from GRAALL‑2014
Hematology-OncologyAcute Lymphoblastic LeukemiaMRD

Age‑Adapted Chemotherapy Plus MRD‑Directed Transplantation Improves Safety Without Sacrificing Efficacy in Ph‑Negative Adult ALL: Key Findings from GRAALL‑2014

By MedXY|Nov 17, 2025

The GRAALL‑2014 trial shows that age‑adapted chemotherapy with MRD‑guided alloHSCT reduces early mortality and transplant use while maintaining disease‑free survival in adults (18–59) with Ph‑negative ALL; 4‑year DFS was 57.1% and overall s

DAGO2 (daunorubicin/cytarabine + fractionated gemtuzumab) Outperforms CPX‑351 in Older Adults with Non‑Adverse‑Risk AML: NCRI AML18 Results
Hematology-OncologyAMLCPX-351

DAGO2 (daunorubicin/cytarabine + fractionated gemtuzumab) Outperforms CPX‑351 in Older Adults with Non‑Adverse‑Risk AML: NCRI AML18 Results

By MedXY|Nov 14, 2025

In older adults (≥60 years) with non‑adverse‑risk AML enrolled in NCRI AML18, daunorubicin/cytarabine plus fractionated gemtuzumab (DAGO2) produced higher early MRD‑negative CR rates and superior 3‑year EFS and OS versus CPX‑351, with parti

Allogeneic HCT in AYA ALL in CR2: MRD-Negativity and Low HCT‑CI Drive Durable Remissions — Dual‑Center Real‑World Outcomes
Hematology-OncologyAcute Lymphoblastic LeukemiaAdolescents and Young Adults

Allogeneic HCT in AYA ALL in CR2: MRD-Negativity and Low HCT‑CI Drive Durable Remissions — Dual‑Center Real‑World Outcomes

By MedXY|Nov 14, 2025

In 164 adolescents and young adults with ALL transplanted in second remission, 3‑year overall survival was 53% and progression‑free survival 46%. MRD positivity and HCT‑Comorbidity Index >3 predicted worse outcomes; female‑to‑male donor

Optimizing Therapy in Transplant-Ineligible Multiple Myeloma: Insights from the REST Phase 2 Trial on Isatuximab, Bortezomib, Lenalidomide, and Limited Dexamethasone
Clinical Updatesclinical trialDexamethasone

Optimizing Therapy in Transplant-Ineligible Multiple Myeloma: Insights from the REST Phase 2 Trial on Isatuximab, Bortezomib, Lenalidomide, and Limited Dexamethasone

By MedXY|Oct 5, 2025

The REST trial demonstrated that combining isatuximab with weekly bortezomib, lenalidomide, and limited dexamethasone yields promising efficacy and manageable safety in older patients with transplant-ineligible multiple myeloma.

Carfilzomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Multiple Myeloma: High MRD Negativity and PFS Benefit in the EMN20 Trial
Clinical UpdatescarfilzomibDexamethasone

Carfilzomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Multiple Myeloma: High MRD Negativity and PFS Benefit in the EMN20 Trial

By MedXY|Oct 1, 2025

The EMN20 phase 3 trial demonstrates that adding carfilzomib to lenalidomide-dexamethasone significantly increases MRD negativity and progression-free survival in transplant-ineligible newly diagnosed multiple myeloma, with manageable toxic

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities